Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis by Behzadifar, Meysam et al.
             Prevalence of Hepatitis C Virus…                                                           Meysam. et al.                       
 
 





Prevalence of Hepatitis C Virus in Tuberculosis Patients: A 
Systematic Review and Meta-Analysis 
 







Citation: Meysam Behzadifar, Sanaz 
Heydarvand, Masoud Behzadifar, Nicola 
Luigi Bragazzi, Meysam Behzadifar, 
Sanaz Heydarvand, Masoud Behzadifar, 
Nicola Luigi Bragazzi. Prevalence of 
Hepatitis C Virus in Tuberculosis Patients: 
A Systematic Review and Meta-Analysis. 
Ethiop J Health Sci. 2018;29(1):945. 
doi:http://dx.doi.org/10.4314/ejhs.v29i1.17  
Received: June 28, 2018 
Accepted: July 15, 2018 
Published: January 1, 2019  
Copyright: © 2018 Meysam Behzadifar, 
B.  et al. This is an open access article 
distributed under the terms of the Creative 
Commons Attribution License, which 
permits unrestricted use, distribution, and 
reproduction in any medium, provided the 
original author and source are credited. 
Funding: Bona District Health Bureau and 
Abem private clinic. 
Competing Interests: The authors declare 
that this manuscript was approved by all 
authors in its form and that no competing 
interest exists. 
Affiliation and Correspondence:  
1Hepatitis Research Center, Lorestan 
University of Medical Sciences, 
Khorramabad, Iran  
2Bahrami Pediatric Hospital, Tehran 
University of Medical Sciences, 
Tehran, Iran  
3Health Management and Economics 
Research Center, Iran University of 
Medical Sciences, Tehran, Iran 
4School of Public Health, Department 
of Health Sciences (DISSAL), 
University of Genoa, Genoa, Italy 
*Email:behzadifar.m@tak.iums.ac.ir,    
masudbehzadifar@gmail.com  
 
        
 





ABSTRACT   
 
      BACKGROUND: Infection with Hepatitis C Virus (HCV) 
increases the hepatotoxicity of anti-tuberculosis drugs. The 
purpose of this systematic review and meta-analysis is to determine 
the prevalence of HCV infection in patients with tuberculosis 
(TB). 
METHODS: PubMed/MEDLINE, ISI/Web of Sciences, CINAHL, 
EMBASE, the Cochrane Library and Scopus were searched from 
January 2000 to March 2018. The overall prevalence of HCV in 
patients with TB was calculated using the random-effect model 
with 95% confidence interval (CI). To evaluate heterogeneity, I2 
test was used. Egger's regression test was utilized to check 
publication bias.  
RESULTS: Twenty-one articles were selected for the final analysis 
based on the inclusion/exclusion criteria. A total of 15,542 patients 
with TB participated in the studies. The overall prevalence of HCV 
infection in patients with TB was 7% [95%CI: 6-9]. Subgroup 
analysis revealed that diagnostic test (P=0.0039), geographical 
background (P=0.0076) and gender distribution (P=0.0672) were 
statistically significant moderators. Men had a higher risk for 
HCV than women (Odds Ratio, OR=2.02; 95%CI: 1.28-3.18). 
CONCLUSION: The results of this study highlighted the 
importance of screening HCV in TB patients. Knowing whether 
HCV is present or not in these patients can be helpful in effectively 
treating them. 
KEYWORDS: Prevalence, hepatitis C virus, tuberculosis, 




Tuberculosis (TB) is recognized as one of the most important public 
health challenges following acquired immune deficiency syndrome 
(AIDS), the second leading cause of death in the world. Each year, 
countries allocate a significant amount of resources in order to 
properly cope with this disease (1,2). In its latest available report, 
the World Health Organization (WHO) estimated that around 10.4 
million people in the world had TB in 2016. The highest incidence 
(45%) was in South-East Asia, followed by, Africa (25%), Western 
Pacific Region (17%), Eastern Mediterranean Region (7%) and 
Europe and the Americas (3%) (3). 
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Hepatitis C Virus (HCV) is another major health 
problem both in developing and developed 
countries, which can cause acute and chronic 
illness in people. About 1.1% of the world's 
population was infected with HCV: 80 million 
had chronic HCV and 495,000 died in 2015 (4,5). 
Most people infected with HCV are not aware of 
their illness, which makes them at risk for liver 
cirrhosis or cancer (6,7). 
With regard to the prevalence of HCV in 
patients with TB and the impact that the infection 
has on these patients, few studies have been 
conducted worldwide, and there is still little 
evidence concerning this topic (8). One of the 
major, clinically relevant side effects in the 
treatment of TB is hepatotoxicity, which disrupts 
the treatment process and may lead to 
discontinuation of the patient's treatment (9,10). 
Hepatotoxicity is one of the side effects of 
Directly Observed Treatment, Short-Course 
(DOTS), first line drugs, which include Rifampin, 
Pyrazinamide, and Isoniazid (11-16). Infection 
with HCV increases the hepatotoxicity of anti-TB 
drugs, and patients with TB should be tested for 
HCV before they start treatment (9). 
The aim of this study is to provide a detailed 
summary of the prevalence of HCV in patients 
with TB. We believe that reducing the effects of 
hepatitis C infection in these patients can be an 
achievable goal when there is precise data on its 
prevalence. In order to provide evidence for 
physicians and healthcare policy- and decision-
makers, the aim of this systematic review and 
meta-analysis is to determine the prevalence of 
HCV infection in patients with TB. 
 
MATERIALS AND METHODS 
 
Search strategy for identifying relevant 
studies: PubMed/MEDLINE, ISI/Web of 
Sciences (WoS), CINAHL, EMBASE, the 
Cochrane Library and Scopus databases were 
searched from January 2000 to March 2018. 
Search strategy was based on the following string 
of keywords: (prevalence OR frequency OR 
epidemiology OR seroprevalence OR 
seroepidemiology OR proportion OR rate) AND 
(hepatitis C virus OR HCV OR viral hepatitis OR 
viral hepatitis C) AND (tuberculosis OR 
Mycobacterium tuberculosis OR mycobacterium 
OR TB). Also, reference lists of included studies 
were reviewed and scanned for possible relevant 
studies. 
Inclusion criteria: Studies were included if they 
were epidemiological studies designed as cross-
sectional, longitudinal or case-control studies. 
They were retained if they examined the 
prevalence of HCV in patients with TB, were 
published in English, had sufficient data to allow 
the calculation of the prevalence, and used 
validated, standardized diagnostic tests such as 
linked immuno-sorbent assay (ELISA), 
recombinant immunoblot assay (RIBA) or 
polymerase chain reaction (PCR) for the diagnosis 
of HCV. Furthermore, studies published between 
January 2000 and March 2018 were selected. 
Exclusion criteria: Studies were excluded if they 
were designed as clinical trials, recruitng TB 
patients who were also HIV positive, containing 
overlapping data or studies whose data were not 
sufficiently detailed to estimate the prevalence 
rate. 
Two researchers independently reviewed 
titles and abstracts of studies for eligibility. After 
selecting the studies, the full texts were reviewed. 
If there was a disagreement between the two 
independent researchers for the selection of the 
studies, a third person was involved as a final 
referee, and the discussion was solved. Selection 
of studies was performed using the EndNote X8 
software. 
Data extraction: From the included articles, we 
obtained the following information: name of first 
author, year of publication, country, geographical 
setting/background based on the continent in 
which the investigation was conducted, mean age 
of participants, diagnostic test utilized, sample 
size, number of TB participants with HCV, 
prevalence estimates, type of TB patients 
(suffering from latent or active TB), and level of 
income based on the definition of the World 
Bank. 
Risk assessment: Internal and external validity, 
response rate and generalization were used to 
evaluate the results of the studies using the Hoy et 
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al criterion (17). This criterion consists of 10 
items that are evaluated based on ‘Yes’ and ‘No’ 
answers. For each answer of ‘Yes’, one point is 
given and for each answer of ‘No’ score is 
assigned. Based on the points obtained, the 
studies were divided into three categories. Studies 
which obtained 0 to 4 points were deemed as at 
high risk, 5 to 7 points at moderate risk and 8 to 
10 at low risk. 
Statistical analysis: All data were analyzed using 
the commercial software Stata Ver.12 (Stata Corp, 
College Station, TX, USA). The overall 
prevalence of HCV in patients with TB was 
calculated using the random-effect model 
according to DerSimonian and Laird's approach 
with 95% confidence interval (CI) (18). To 
evaluate heterogeneity, I2 test was used. The 
values of 25%, 50% and 75% were considered to 
indicate low, moderate and high amounts of 
heterogeneity, respectively (19). Sensitivity 
analysis was performed to ensure the stability of 
the results. In this analysis, the effect of omitting 
each study per time was examined (20). The 
studies were, then, ranked according to the year of 
publication and the sample size, and cumulative 
meta-analysis was performed to determine the 
effect of these factors on the prevalence of HCV 
(21).  
In order to examine possible sources of 
heterogeneity, sub-group analyses were conducted 
based on the year of study publication, sample 
size, quality of studies, diagnostic test, geographic 
background, level of income (based on the 
definition of the World Bank) and type of TB 
(active or latent).  
Meta-regression was also conducted based 
on the year of study publication. Egger’s test was 
used to check the publication bias (22). Duval and 
Tweedie’s trim-and-fill method was used to 
evaluate the effect of potentially missing studies 
(publication bias), whose effect sizes could 
possibly modify the estimated prevalence rate of 
HCV (23).  
The Cohen’s Kappa coefficient was used for 
quantitatively assessing the agreement between 
researchers on the selection of studies, data 
extraction and methodological quality assessment 
(24). All figures with two-sided P-value <0.05 




Study selection: Reporting of the results of this 
systematic review and meta-analytical study was 
carried out in accordance with the “Preferred 
Reporting Items for Systematic Reviews and 
Meta-analyses” (PRISMA) guidelines  (25). The 
process of selecting studies is pictorially 
presented in Figure 1.  
In the initial search, 535 studies were 
identified from the different scholarly databases. 
After removing duplicates, searches led to a pool 
of 354 studies. After reviewing the title and 
abstract of the studies, 43 studies remained. The 
full texts of the studies were reviewed, and 21 
were selected for the final analysis based on 
inclusion/exclusion criteria (9,26-45). The 
agreement between the two independent 
researchers was 92.17% for the selection of 
studies. 
Study and participant characteristics: A total of 
15,542 patients with TB participated in the 
studies. Seven studies were conducted in Europe, 
6 studies in Asia, 5 studies in America and 3 
studies in Africa. Table 1 shows the main 
characteristics of the included studies. 
Risk of bias within studies: After reviewing the 
articles, 12 (57.14%) of them were deemed at low 
risk, 6(28.57%) had moderate risk and 3(14.29%) 
were considered at high risk. The agreement 
between the two independent researchers was 
84.26% for risk assessment. 
The pooled prevalence of HCV in TB patients: 
The prevalence of HCV in TB patients was 2% to 
27%. Based on the random-effect model, the 
overall prevalence was 7% [95%CI: 6-9]. The 
heterogeneity was high between studies 
(I=94.2%; P <0.0001) (Figure 2). 
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Figure 1: Flowchart of study selection 
 
   
Figure 2:  Prevalence of HCV in TB patients with 95% confidence interval for each included study  
 
NOTE: Weights are from random effects analysis
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Results of subgroup analysis: The prevalence 
rates based on the diagnostic test, sample size, 
geographical background, risk assessment of the 
study and gender of the participants are shown in 
Table 2. 
 
Table 1: Characteristics of the included studies 
 
First author  Year Country Age (Mean±SD) Test Prevalence No. of participants 
Richards 2006 Georgia 35 ELISA 22% 272 
Kuniholm 2008 Georgia NA ELISA 12.00% 300 
Pando 2008 Argentina 34.8±14.1 ELISA 11.80% 187 
Khalili 2009 Iran 43.21±18.27 ELISA 27.45% 102 
Khan 2010 UK NA ELISA 2.00% 245 
Chien 2010 Taiwan NA ELISA 10% 295 
Wang 2011 Taiwan NA PCR 6.70% 360 
Reis 2011 Brazil NA ELISA 7.50% 402 
Badawy 2011 Egypt NA ELISA 6.40% 135 
Lomtadze 2013 Georgia 21-92 ELISA 21% 326 
Akhtar 2013 Pakistan 42±18.2 ELISA 9.10% 110 
Beasley 2013 UK NA ELISA NA 192 
Zhang 2013 China NA ELISA 3.80% 2296 
Potter 2014 UK 37.7±15.3 ELISA 2.00% 302 
Campo 2014 USA NA ELISA 3.60% 1421 
Agha 2015 Egypt NA PCR 17.02% 94 
Ahmadi Nooredinvand 2015 UK NA ELISA 1.60% 429 
Abdallah 2015 Sudan 36.03± 13.3 ELISA 1% 98 
Bushnell 201+5 USA NA ELISA 4.20% 7624 
Merza 2016 Iraq 40.34±20.29 ELISA 0.90% 214 
Costi 2017 Brazil 38.0± 12.9 PCR 20% 138 
 
Diagnostic test: ELISA tests were used to detect 
HCV in 13 studies, with a prevalence of 7% 
[95%CI: 5-8]. PCR tests were performed in 3 
studies with a prevalence of 14% [95%CI: 23-23]. 
This difference was statistically significant 
(P=0.0039). 
Sample size: The estimated prevalence in studies 
with a sample size of less than or equal to 250 
participants was higher (9% [95%CI: 6-9]) 
compared to studies with a sample size greater 
than 250 (7% [95%CI: 5-9]). However, this 
difference was not statistically significant. 
Geographical background: The highest 
prevalence was found in Africa (11% [95%CI: 1-
23]), followed by Europe (9% [95%CI: 4-13]), 
America (7% [95%CI: 4-10]) and Asia (7% 
[95%CI: 4-11]). This difference was statistically 
significant (P=0.0076). 
Risk of bias: The prevalence stratified according 
to the risk of bias was 9% [95%CI: 11-7] in 12 
studies at low risk of bias, 9% [95%CI: 13-4] in 6 
studies at moderate risk, and 2% [95%CI: 1-3] in 
studies at high risk. These differences were not 
significant.  
Prevalence of HCV and gender: The prevalence 
rate of HCV in TB men was collected from 8 
studies (10% [95%CI: 14-16]) and in women 
from other 8 studies (2% [95%CI: 1-4]). This 
difference was statistically significant (P=0.0672). 
This finding showed that men had a higher risk 
for HCV than women (Odds Ratio, OR=2.02 
[95%CI: 1.28-3.18]) (Figure 3). 
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Table 2: Subgroup analyses of prevalence of HCV in TB patients. Abbreviations: ns (not statistically 
significant). 
 







Heterogeneity value P value 
I2 (%) P value 
Diagnostic test      0.0039 
ELISA 18 14950 7% (5-8) 94.3% <0.0001 
 
PCR 3 592 14% (5-23) 88.4% <0.0001 
Sample size      <0.0001 
≤ 250 10 1515 9% (6-9) 93.1% <0.0001  
 >250 11 14027 7% (5-9) 95.2% <0.0001 
Geographical 
background 
     0.0076 





Asia  6 3377 7% (4-11) 94.6% <0.0001 
America 5 9772 7% (4-10) 93.5% <0.0001 
Europa  7 2066 9% (4-13) 96.0% <0.0001 
Risk of bias       
Low  12 13742 9% (7-11) 95.5% <0.0001  
 Moderate  6 1061 9% (4-13) 94.3% <0.0001 
High   3 739 2% (1-3) 0.0% ns 
Gender       0.0672 
Male  8 5821 10% (6-14) 94.1% <0.0001 
 
Female  8 3838 3% (1-4) 74.0% <0.0001 
Level of income       <0.0001 
Lower middle 7 1335 14% (6-21) 95.3% <0.0001  
Upper middle 6 3339 9% (6-13) 95.6% <0.0001 
 
High 8 10868 3% (2-4) 81.3% <0.0001  
Type of TB      <0.0001 
Active  18 14676 9% (7-10) 95.0% <0.0001 
 
Both (Active and 
latent) 
3 866 2% (1-3) 0.0% ns  
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Figure 3: Meta-analysis of the Odds Ratio (OR) for prevalence of HCV in TB patients in male subjects compared to 
female individuals  
 
Level of income: The prevalence of HCV in TB 
was 14% [95%CI: 6-21] in lower middle income 
settings, 9% [95%CI: 6-13] in upper middle 
income contexts and 3% [95%CI: 2-4] in high 
income countries.  
Type of TB: The prevalence was 9% [95%CI: 7-
10] in studies with active TB patients and 2% 
[95%CI: 1-3] in studies with active or latent TB 
patients.  
Meta-regression: The prevalence of HCV in TB 
patients was assessed based on the published 
years, and significant changes were observed 
(P=0.049). 
Sensitivity analysis: By omitting each study, its 
effect on the overall prevalence rate was 
evaluated, and the sensitivity analysis indicated 
that the results before and after did not change in 
a significant way, which indicates the stability of 
the results. 
Cumulative meta-analysis: Cumulative meta-
analysis was performed by sorting studies based 
on the year of publication and sample size. When 
the studies were sorted according to the year of 
publication, their 95% CI during the years of 
study release revealed an increase in the rate of 
HCV in TB patients. Also, when studies were 
sorted according to sample size, 95% CI showed a 
decrease in the rate of HCV in TB patients. 
 
Publication bias: Publication bias was computed 
performing the Egger’s regression test, and the 
results indicated a bias in published studies 
(P=0.000). Due to this bias, the Trim and Fill test 
was performed and found 7 censored studies and 
their potential effects on the prevalence rate.  
Risk factors for HCV in TB: Some selected 
studies identified the risk factors for HCV in TB 
patients. These risk factors included: history of 
sexually transmitted infections (STIs), tattoo and 
body piercing, history of prison or correctional 
services, history of injection drugs use (IDU), 
history of surgery, blood transfusion, dental 
services, smoking, alcohol consumption, family 
history of hepatitis C, use of personal objects 




To the best of our knowledge, this study is the 
first meta-analysis to comprehensively address the 
prevalence of HCV in TB patients worldwide. A 
total of 21 studies were selected using a 
comprehensive search strategy in validated 
databases. The sensitivity analysis confirmed that 
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the results were stable. The cumulative meta-
analysis, based on the year of publication revealed 
a decrease in the rate of HCV. 
The prevalence of HCV in TB patients 
reported in this study was higher than the 
incidence of HCV in HIV positive patients 
according to some studies of the literature (46,47). 
Also, the prevalence in this study is higher than 
the incidence of HCV in the general population, 
according to a recent meta-analytical study (48). 
On the other hand, when compared to 
hemodialysis patients, the prevalence of HCV in 
TB patients was found to be lower (49).  
An increasingly rising prevalence rate of TB 
worldwide has led the WHO to propose a DOTS-
based approach. This strategy, which treats 
patients for 6 months, is the most effective, 
practical and proper way to treat the disease 
(50,51). 
Estimates of hepatotoxicity induced by 
Rifampicin, Isoniazid and Pyrazamide are 
difficult to compute due to variability among 
patients in terms of physical and psychological 
characteristics. Chronic liver diseases, such as 
viral infections, can increase hepatotoxicity (52-
54). In TB patients with hepatitis C, the risk of 
hepatotoxicity is higher than that of TB patients 
who do not suffer from hepatitis C (11,55). 
Studies show that HCV infection in TB patients 
can cause a significant change in the number of T 
CD4 + lymphocytes (56-58). In patients with TB, 
HCV levels increase the concentrations of liver 
enzymes. However, there is still no clear 
relationship between HCV and increased risk of 
hepatotoxicity (56-58). 
Our findings showed that the reported 
prevalence was significantly different depending 
on the diagnostic tests used: the geographical 
background, the highest prevalence of HCV in TB 
patients was observed in African countries. The 
health conditions of countries play an important 
role in the spread of various diseases, including 
HCV and TB. Public health and health care 
services have problems to be delivered programs 
major impact on the prevalence of infectious 
diseases in these countries. 
In many countries, including developing 
countries, many public health officials are 
unaware of the impact of infectious diseases, and, 
unfortunately, do not provide the right conditions 
for screening and healthcare (63). In previous 
studies, there is little information about the 
difference between social, health, cultural and 
economic backgrounds. These differences should 
be noticed in future studies. 
The findings of this study showed that the 
prevalence of HCV in male TB patients was 
higher than that in women (RR=1.89). In studies, 
high risk behaviors were reported in men more 
than in women, which made them being more at 
risk for HCV. Some studies have shown that 
behaviors such as IDU, the use of common 
syringes, tattoos, body piercing and alcohol 
consumption were higher in men than in women, 
and, consequently, the prevalence rate of HCV 
was higher (64, 65). 
Meta-regression according to the year of 
publication of studies indicated a reduction in the 
rate of HCV in TB patients. This can be due to 
several factors. Over the past decades, better 
health conditions and wider access to health 
services worldwide have improved for prevention 
and control of HCV. Screening and training in 
high-risk groups (drug users, prisoners) and 
special populations by the health system in 
various countries has, also, significantly and 
positively impacted on the control and 
management of infectious diseases (66). 
The risk factors for HCV in TB patients 
that have been reported by selected studies 
are among the most recognized risk factors 
mentioned in various studies in the world. 
Health decision- and policy-makers and 
primary healthcare providers must implement 
special programs for people at risk. Paying 
attention to these people reduces significantly 
the prevalence of the disorder (67-69).  
However, despite some strengths, 
including its novelty and the broad and 
comprehensive search strategy, this study has 
the following limitations: 
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a. Due to the fact that there is a methodological 
diversity among the studies, there is a 
significant heterogeneity in this meta-
analysis, which could affect results and their 
generalization. 
b. In many parts of the world, studies have not 
been conducted, which could impact on the 
overall estimated prevalence rate of HCV in 
TB patients. 
c. Diagnostic tests used in studies, gender and 
geographic context as potential 
heterogeneity sources and bias observed in 
studies make it possible to interpret the 
results with caution. 
Taking the above-mentioned shortcomings into 
account, the results of this study highlighted the 
importance of performing HCV screening in TB 
patients. Knowing whether HCV is present or not 
in these patients can be helpful in effectively 
treating them. Healthcare decision- and policy-
makers need to implement ad hoc measures to 
educate and screen groups at high risk for 
developing HCV and TB. 
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